{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:51:52Z","timestamp":1793407912623,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["R21EY036185-01"],"award-info":[{"award-number":["R21EY036185-01"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["P30 EY030413"],"award-info":[{"award-number":["P30 EY030413"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["P30 EY030413"],"award-info":[{"award-number":["P30 EY030413"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA142543"],"award-info":[{"award-number":["P30 CA142543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uveal melanoma (UM) is the most common adult primary intraocular malignancy, with a strong predilection for hepatic metastasis, occurring in approximately 50% of cases. Metastatic UM is highly resistant to therapy and is almost invariably fatal. The strongest genetic driver of UM metastasis is loss of function of the tumor suppressor BRCA-associated protein 1 (BAP1), which leads to widespread epigenetic dysregulation. To identify novel therapeutic strategies, we investigated whether targeting the epigenome of UM could reveal new vulnerabilities. We performed a high-throughput compound screen using a curated epigenetic inhibitor library and identified BET (bromodomain and extra-terminal domain) inhibition as a particularly promising approach. While previous clinical trials with BET inhibitors for UM treatment have failed, we found substantial heterogeneity in the efficacy of different BET inhibitors in UM. Notably, the BET inhibitor mivebresib (ABBV-075) significantly improved survival rates by 50% in a metastatic UM xenograft mouse model and prevented detectable metastases in the bones, spinal cord, and brain. Transcriptomic analysis revealed a strong overlap between BET and histone deacetylase (HDAC) inhibition, an approach currently under clinical evaluation for UM treatment. BET and HDAC inhibitors reversed gene expression signatures associated with high metastatic risk and induced a neuron-like phenotype in UM cells. These findings establish BET inhibition as a potent and previously underappreciated vulnerability for metastatic UM.<\/jats:p>","DOI":"10.1038\/s41419-025-08295-4","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:15:56Z","timestamp":1765538156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of targetable epigenetic vulnerabilities for uveal melanoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Gulum","family":"Yenisehirli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffanie S.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley N.","family":"Zuniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela I.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffim N.","family":"Kutsnetsoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata L.","family":"Volonterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily V.","family":"Adis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Dollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Stathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Henry","family":"Volmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efe","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun P.","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William","family":"Harbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelia M.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-596X","authenticated-orcid":false,"given":"Stefan","family":"Kurtenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"8295_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20:99\u2013115.","journal-title":"Nat Rev Clin Oncol"},{"key":"8295_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"8295_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","volume":"134","author":"CL Decatur","year":"2016","unstructured":"Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134:728\u201333.","journal-title":"JAMA Ophthalmol"},{"key":"8295_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","volume":"457","author":"CD Van Raamsdonk","year":"2009","unstructured":"Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O\u2019Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599\u2013602.","journal-title":"Nature"},{"key":"8295_CR5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191\u20139.","journal-title":"N Engl J Med"},{"key":"8295_CR6","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.6614","volume":"7","author":"P Johansson","year":"2016","unstructured":"Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7:4624.","journal-title":"Oncotarget"},{"key":"8295_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ng.3549","volume":"48","author":"AR Moore","year":"2016","unstructured":"Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016;48:675\u201380.","journal-title":"Nat Genet"},{"key":"8295_CR8","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1167\/iovs.08-2145","volume":"49","author":"MD Onken","year":"2008","unstructured":"Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Investig Opthalmol Vis Sci. 2008;49:5230.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"8295_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/bjc.2017.259","volume":"117","author":"M Vader","year":"2017","unstructured":"Vader M, Madigan M, Versluis M, Suleiman H, Gezgin G, Gruis NA, et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer. 2017;117:884\u20137.","journal-title":"Br J Cancer"},{"key":"8295_CR10","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. SCIENCE. 2010;330:1410\u20133.","journal-title":"SCIENCE"},{"key":"8295_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45:133\u20135.","journal-title":"Nat Genet"},{"key":"8295_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin M, Ma\u00dfh\u00f6fer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933\u20136.","journal-title":"Nat Genet"},{"key":"8295_CR13","doi-asserted-by":"publisher","first-page":"a004051","DOI":"10.1101\/mcs.a004051","volume":"5","author":"MA Durante","year":"2019","unstructured":"Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, et al. Genomic evolution of uveal melanoma arising in ocular melanocytosis. Mol Case Stud. 2019;5:a004051.","journal-title":"Mol Case Stud"},{"key":"8295_CR14","doi-asserted-by":"crossref","unstructured":"Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11:496.","DOI":"10.1038\/s41467-019-14256-1"},{"key":"8295_CR15","doi-asserted-by":"crossref","unstructured":"Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun 2018;9:116.","DOI":"10.1038\/s41467-017-02428-w"},{"key":"8295_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08255-x","volume":"10","author":"A Campagne","year":"2019","unstructured":"Campagne A, Lee M-K, Zielinski D, Michaud A, Le Corre S, Dingli F, et al. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat Commun. 2019;10:348.","journal-title":"Nat Commun"},{"key":"8295_CR17","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1128\/MCB.00396-10","volume":"30","author":"H Yu","year":"2010","unstructured":"Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol. 2010;30:5071\u201385.","journal-title":"Mol Cell Biol"},{"key":"8295_CR18","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1158\/1078-0432.CCR-19-0366","volume":"25","author":"MG Field","year":"2019","unstructured":"Field MG, Kuznetsov JN, Bussies PL, Cai LZ, Alawa KA, Decatur CL, et al. BAP1 loss is associated with DNA methylomic repatterning in highly aggressive class 2 uveal melanomas. Clin Cancer Res. 2019;25:5663.","journal-title":"Clin Cancer Res"},{"key":"8295_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax1738","volume":"5","author":"JN Kuznetsov","year":"2019","unstructured":"Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S, Field MG, Durante MA, et al. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019;5:eaax1738.","journal-title":"Sci Adv"},{"key":"8295_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25529-z","volume":"12","author":"MF Bakhoum","year":"2021","unstructured":"Bakhoum MF, Francis JH, Agustinus A, Earlie EM, Di Bona M, Abramson DH, et al. Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression. Nat Commun. 2021;12:5402.","journal-title":"Nat Commun"},{"key":"8295_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"M Carbone","year":"2020","unstructured":"Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 2020;10:1103\u201320.","journal-title":"Cancer Discov"},{"key":"8295_CR22","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-09-3066","volume":"16","author":"F N\u00e9mati","year":"2010","unstructured":"N\u00e9mati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and\/or metastatic tumors. Clin Cancer Res. 2010;16:2352\u201362.","journal-title":"Clin Cancer Res"},{"key":"8295_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1081\/CNV-120030218","volume":"22","author":"J Adams","year":"2004","unstructured":"Adams J, Kauffman M. Development of the proteasome inhibitor Velcade\u2122(Bortezomib). Cancer Investig. 2004;22:304\u201311.","journal-title":"Cancer Investig"},{"key":"8295_CR24","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","volume":"17","author":"A Schmittel","year":"2006","unstructured":"Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis N, Schuster R, Siehl J, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006;17:1826\u20139.","journal-title":"Ann Oncol"},{"key":"8295_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/1541-7786.MCR-18-0574","volume":"17","author":"D Lapadula","year":"2019","unstructured":"Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, et al. Effects of oncogenic G\u03b1q and G\u03b111 inhibition by FR900359 in uveal melanoma. Mol Cancer Res. 2019;17:963\u201373.","journal-title":"Mol Cancer Res"},{"key":"8295_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb07020.x","volume":"922","author":"LF Liu","year":"2000","unstructured":"Liu LF, Desai SD, LI TK, Mao Y, Sun M, SIM SP. Mechanism of action of camptothecin. Ann N Y Acad Sci. 2000;922:1\u201310.","journal-title":"Ann N Y Acad Sci"},{"key":"8295_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2014.10.011","volume":"113","author":"TJ Gardner","year":"2015","unstructured":"Gardner TJ, Cohen T, Redmann V, Lau Z, Felsenfeld D, Tortorella D. Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle. Antivir Res. 2015;113:49\u201361.","journal-title":"Antivir Res"},{"key":"8295_CR28","first-page":"19","volume":"52","author":"S Garg","year":"2018","unstructured":"Garg S, Kaul SC, Wadhwa R. Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms. Int J Oncol. 2018;52:19\u201337.","journal-title":"Int J Oncol"},{"key":"8295_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin cancer Res. 2012;18:408.","journal-title":"Clin cancer Res"},{"key":"8295_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1541-7786.MCR-20-0434","volume":"19","author":"JN Kuznetsoff","year":"2021","unstructured":"Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, et al. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. Mol cancer Res. 2021;19:215.","journal-title":"Mol cancer Res"},{"key":"8295_CR31","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.21873\/anticanres.12665","volume":"38","author":"MM Moschos","year":"2018","unstructured":"Moschos MM, Dettoraki M, Androudi S, Kalogeropoulos D, Lavaris A, Garmpis N, et al. The role of histone deacetylase inhibitors in uveal melanoma: current evidence. Anticancer Res. 2018;38:3817\u201324.","journal-title":"Anticancer Res"},{"key":"8295_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2017.04.028","volume":"400","author":"Y Wang","year":"2017","unstructured":"Wang Y, Liu M, Jin Y, Jiang S, Pan J. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. Cancer Lett. 2017;400:47\u201360.","journal-title":"Cancer Lett"},{"key":"8295_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep22622","volume":"6","author":"W Dai","year":"2016","unstructured":"Dai W, Zhou J, Jin B, Pan J. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016;6:22622.","journal-title":"Sci Rep"},{"key":"8295_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nsmb1239","volume":"14","author":"E Nicolas","year":"2007","unstructured":"Nicolas E, Yamada T, Cam HP, FitzGerald PC, Kobayashi R, Grewal SI. Distinct roles of HDAC complexes in promoter silencing, antisense suppression and DNA damage protection. Nat Struct Mol Biol. 2007;14:372\u201380.","journal-title":"Nat Struct Mol Biol"},{"key":"8295_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009;277:8\u201321.","journal-title":"Cancer Lett"},{"key":"8295_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","volume":"64","author":"KM VanderMolen","year":"2011","unstructured":"VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot. 2011;64:525\u201331.","journal-title":"J Antibiot"},{"key":"8295_CR37","doi-asserted-by":"crossref","unstructured":"Gentien D, Saberi-Ansari E, Servant N, Jolly A, de la Grange P, N\u00e9mati F, et al. Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma. Cell Rep. 2023;42:113132.","DOI":"10.1016\/j.celrep.2023.113132"},{"key":"8295_CR38","doi-asserted-by":"crossref","unstructured":"Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021;34:108638.","DOI":"10.1016\/j.celrep.2020.108638"},{"key":"8295_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","volume":"399","author":"C Dhalluin","year":"1999","unstructured":"Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou M-M, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399:491\u20136.","journal-title":"Nature"},{"key":"8295_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19:535\u201345.","journal-title":"Mol Cell"},{"key":"8295_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32205-3","volume":"13","author":"M Pilarczyk","year":"2022","unstructured":"Pilarczyk M, Fazel-Najafabadi M, Kouril M, Shamsaei B, Vasiliauskas J, Niu W, et al. Connecting omics signatures and revealing biological mechanisms with iLINCS. Nat Commun. 2022;13:4678.","journal-title":"Nat Commun"},{"key":"8295_CR42","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","volume":"64","author":"MD Onken","year":"2004","unstructured":"Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205\u20139.","journal-title":"Cancer Res"},{"key":"8295_CR43","doi-asserted-by":"crossref","unstructured":"Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol. Biol. 2014:427\u201340.","DOI":"10.1007\/978-1-62703-727-3_22"},{"key":"8295_CR44","unstructured":"Harbour JW, Chen R. The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr 2013;5:ecurrents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618."},{"key":"8295_CR45","doi-asserted-by":"crossref","unstructured":"Kurtenbach S, Sanchez MI, Kuznetsoff J, Rodriguez DA, Weich N, Dollar JJ, et al. PRAME induces genomic instability in uveal melanoma. Oncogene. 2023:1\u201311.","DOI":"10.1038\/s41388-023-02887-0"},{"key":"8295_CR46","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S, Gezgin G, Van Der Velden PA, Jager MJ, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22:1234\u201342.","journal-title":"Clin Cancer Res"},{"key":"8295_CR47","unstructured":"Harbour JW, Correa ZM, Schefler AC, Mruthyunjaya P, Materin MA, Aaberg TA, Jr. et al. 15-gene expression profile and PRAME as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (COOG2.1). J Clin Oncol. 2024:JCO2400447."},{"key":"8295_CR48","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","volume":"26","author":"A Lachmann","year":"2010","unstructured":"Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma\u2019ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics. 2010;26:2438\u201344.","journal-title":"Bioinformatics"},{"key":"8295_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10792-024-02943-y","volume":"44","author":"X Bai","year":"2024","unstructured":"Bai X, Li S, Luo Y. FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression. Int Ophthalmol. 2024;44:55.","journal-title":"Int Ophthalmol"},{"key":"8295_CR50","doi-asserted-by":"publisher","first-page":"768594","DOI":"10.1155\/2014\/768594","volume":"2014","author":"RA Quintanilla","year":"2014","unstructured":"Quintanilla RA, Utreras E, Cabezas-Opazo FA. Role of PPAR\u03b3 in the differentiation and function of neurons. PPAR Res. 2014;2014:768594.","journal-title":"PPAR Res"},{"key":"8295_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mce.2017.07.033","volume":"471","author":"Z Simandi","year":"2018","unstructured":"Simandi Z, Horvath A, Cuaranta-Monroy I, Sauer S, Deleuze J-F, Nagy L. RXR heterodimers orchestrate transcriptional control of neurogenesis and cell fate specification. Mol Cell Endocrinol. 2018;471:51\u201362.","journal-title":"Mol Cell Endocrinol"},{"key":"8295_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0303-7207(99)00115-X","volume":"155","author":"A Schmidt","year":"1999","unstructured":"Schmidt A, Vogel R, Holloway MK, Rutledge SJ, Friedman O, Yang Z, et al. Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family. Mol Cell Endocrinol. 1999;155:51\u201360.","journal-title":"Mol Cell Endocrinol"},{"key":"8295_CR53","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/cancers13153862","volume":"13","author":"C Mayr","year":"2021","unstructured":"Mayr C, Kiesslich T, Erber S, Bekric D, Dobias H, Beyreis M, et al. HDAC screening identifies the HDAC class I inhibitor romidepsin as a promising epigenetic drug for biliary tract cancer. Cancers. 2021;13:3862.","journal-title":"Cancers"},{"key":"8295_CR54","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.4161\/cc.9.9.11543","volume":"9","author":"J Panicker","year":"2010","unstructured":"Panicker J, Li Z, McMahon C, Sizer C, Steadman K, Piekarz R, et al. Romidepsin (FK228\/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell cycle. 2010;9:1830\u20138.","journal-title":"Cell cycle"},{"key":"8295_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.biopha.2016.04.053","volume":"82","author":"L-H Li","year":"2016","unstructured":"Li L-H, Zhang P-R, Cai P-Y, Li Z-C. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway. Biomed Pharmacother. 2016;82:161\u20136.","journal-title":"Biomed Pharmacother"},{"key":"8295_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1078155216673229","volume":"24","author":"ZT Rivers","year":"2018","unstructured":"Rivers ZT, Oostra DR, Westholder JS, Vercellotti GM. Romidepsin-associated cardiac toxicity and ECG changes: a case report and review of the literature. J Oncol Pharm Pract. 2018;24:56\u201362.","journal-title":"J Oncol Pharm Pract"},{"key":"8295_CR57","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1158\/1078-0432.CCR-07-0318","volume":"14","author":"VM Klimek","year":"2008","unstructured":"Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008;14:826\u201332.","journal-title":"Clin Cancer Res"},{"key":"8295_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111483","volume":"125","author":"W Liu","year":"2025","unstructured":"Liu W, Cui Z, Wan Q, Liu Y, Chen M, Cheng Y, et al. The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma. Cell Signal. 2025;125:111483.","journal-title":"Cell Signal"},{"key":"8295_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.65.8.11","volume":"65","author":"X Chen","year":"2024","unstructured":"Chen X, Huang R, Zhang Z, Song X, Shen J, Wu Q. Bet bromodomain inhibition potentiates ocular melanoma therapy by inducing cell cycle arrest. Investig Ophthalmol Vis Sci. 2024;65:11.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"8295_CR60","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/cancers11060846","volume":"11","author":"M Croce","year":"2019","unstructured":"Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted therapy of uveal melanoma: Recent failures and new perspectives. Cancers. 2019;11:846.","journal-title":"Cancers"},{"key":"8295_CR61","doi-asserted-by":"crossref","unstructured":"Patnaik A, Carvajal RD, Komatsubara KM, Britten CD, Wesolowski R, Michelson G, et al. Phase ib\/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors. Am Soc Clin Oncol 2018;36:2550.","DOI":"10.1200\/JCO.2018.36.15_suppl.2550"},{"key":"8295_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/pcmr.13161","volume":"37","author":"XL Liu","year":"2024","unstructured":"Liu XL, Run-Hua Z, Pan JX, Li ZJ, Yu L, Li YL. Emerging therapeutic strategies for metastatic uveal melanoma: targeting driver mutations. Pigment Cell Melanoma Res. 2024;37:411\u201325.","journal-title":"Pigment Cell Melanoma Res"},{"key":"8295_CR63","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"Group TCOMS.","year":"2001","unstructured":"Group TCOMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670\u20136.","journal-title":"Arch Ophthalmol"},{"key":"8295_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961517","volume":"12","author":"AZ Wei","year":"2022","unstructured":"Wei AZ, Uriel M, Porcu A, Manos MP, Mercurio AC, Caplan MM, et al. Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Front Oncol. 2022;12:961517.","journal-title":"Front Oncol"},{"key":"8295_CR65","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1084\/jem.20151271","volume":"212","author":"JM Sullivan","year":"2015","unstructured":"Sullivan JM, Badimon A, Schaefer U, Ayata P, Gray J, Chung C-w, et al. Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice. J Exp Med. 2015;212:1771\u201381.","journal-title":"J Exp Med"},{"key":"8295_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.wneu.2022.03.051","volume":"162","author":"V Govindarajan","year":"2022","unstructured":"Govindarajan V, Shah AH, Di L, Rivas S, Suter RK, Eichberg DG, et al. Systematic review of epigenetic therapies for treatment of IDH-mutant glioma. World Neurosurg. 2022;162:47\u201356.","journal-title":"World Neurosurg"},{"key":"8295_CR67","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.21873\/invivo.12872","volume":"36","author":"DH Albert","year":"2022","unstructured":"Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, et al. Co-clinical modeling of the activity of the BET inhibitor mivebresib (ABBV-075) in AML. vivo. 2022;36:1615\u201327.","journal-title":"vivo"},{"key":"8295_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1541-7786.MCR-16-0221","volume":"15","author":"EJ Faivre","year":"2017","unstructured":"Faivre EJ, Wilcox D, Lin X, Hessler P, Torrent M, He W, et al. Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075. Mol Cancer Res. 2017;15:35\u201344.","journal-title":"Mol Cancer Res"},{"key":"8295_CR69","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-16-0459","volume":"16","author":"LT Lam","year":"2017","unstructured":"Lam LT, Lin X, Faivre EJ, Yang Z, Huang X, Wilcox DM, et al. Vulnerability of small-cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors. Mol Cancer Ther. 2017;16:1511\u201320.","journal-title":"Mol Cancer Ther"},{"key":"8295_CR70","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","volume":"25","author":"SA Piha-Paul","year":"2019","unstructured":"Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors. Clin Cancer Res. 2019;25:6309\u201319.","journal-title":"Clin Cancer Res"},{"key":"8295_CR71","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s00221-006-0831-x","volume":"176","author":"FA Siebzehnrubl","year":"2007","unstructured":"Siebzehnrubl FA, Buslei R, Eyupoglu IY, Seufert S, Hahnen E, Blumcke I. Histone deacetylase inhibitors increase neuronal differentiation in adult forebrain precursor cells. Exp Brain Res. 2007;176:672\u20138.","journal-title":"Exp Brain Res"},{"key":"8295_CR72","doi-asserted-by":"publisher","first-page":"16659","DOI":"10.1073\/pnas.0407643101","volume":"101","author":"J Hsieh","year":"2004","unstructured":"Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci. 2004;101:16659\u201364.","journal-title":"Proc Natl Acad Sci"},{"key":"8295_CR73","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.scr.2016.07.006","volume":"17","author":"J Li","year":"2016","unstructured":"Li J, Ma J, Meng G, Lin H, Wu S, Wang J, et al. BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. Stem Cell Res. 2016;17:212\u201321.","journal-title":"Stem Cell Res"},{"key":"8295_CR74","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping MT, Wang L, Edel MJ, Carl\u00e9e L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122:835\u201347.","journal-title":"Cell"},{"key":"8295_CR75","doi-asserted-by":"crossref","unstructured":"Le Douarin N, Kalcheim C. The neural crest: Cambridge University Press; 1999.","DOI":"10.1017\/CBO9780511897948"},{"key":"8295_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-371","volume":"13","author":"KA Matatall","year":"2013","unstructured":"Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013;13:1\u201312.","journal-title":"BMC Cancer"},{"key":"8295_CR77","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cels.2018.10.007","volume":"7","author":"D Torre","year":"2018","unstructured":"Torre D, Lachmann A, Ma\u2019ayan A. BioJupies: automated generation of interactive notebooks for RNA-Seq data analysis in the cloud. Cell Syst. 2018;7:556\u201361.e3.","journal-title":"Cell Syst"},{"key":"8295_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"8295_CR79","unstructured":"Abcam. Immunocytochemistry protocol: Abcam; 2022 [Available from: https:\/\/www.abcam.com\/en-us\/technical-resources\/protocols\/icc-protocol?srsltid=AfmBOoqyt4JzQIg_lE0OOXDD4ho0XaMzPhyNsZIHA97qu47Q0IKgCbGx."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08295-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:03:32Z","timestamp":1769184212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08295-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8295"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08295-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. The University of Miami Institutional Animal Care and Use Committee (IACUC) approved all animal procedures (reference number: IACUC 21-073). No human research participants were included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"89"}}